Regulatory Update
|
13 June 2012
0 Likes
The UK’s National Institute for Health and Clinical Excellence (NICE) has reversed an earlier decision and now plans to recommend the use of Amgen’s new cancer drug denosumab, used in the treatment of
Read More...